Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bayer AGXSWX:BAYN 45 EV-to-OCF is 14.76 as of Jul. 14, 2026, which is 69% above its 10-year median of 8.72. GuruFocus rates XSWX:BAYN with a GF Score™ of 45/100 and a GF Value™ of CHF24.67 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Bayer AG ranks worse than 60.32% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Bayer AG's Enterprise Value is CHF71,659 Mil.
Bayer AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was CHF4,855 Mil. Therefore, Bayer AG's EV-to-OCF for today is 14.76.
The historical rank and industry rank for Bayer AG's EV-to-OCF or its related term are showing as below:
XSWX:BAYN'
s EV-to-OCF Range Over the Past 10 Years
Min: 1.55 Med: 8.72 Max: 22.7
Current: 15.13
During the past 13 years, the highest EV-to-OCF of Bayer AG was 22.70. The lowest was 1.55. And the median was 8.72.
XSWX:BAYN's EV-to-OCF is ranked worse than 60.32% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.58
vs XSWX:BAYN: 15.13
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bayer AG's share price for today is CHF47.36.
Bayer AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-2.111.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bayer AG EV-to-OCF Related Terms
Bayer AG EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Bayer AG's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Bayer AG's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Bayer AG's EV-to-OCF falls into.
Bayer AG's current Enterprise Value is CHF71,659 Mil.
Bayer AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF4,855 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG (XSWX:BAYN) has a EV-to-OCF of 14.76 as of Jul. 14, 2026. This is 69% above median its historical median of 8.72. Over the past decade, Bayer AG's EV-to-OCF has ranged from 1.55 to 22.70. According to the industry distribution chart, Bayer AG ranks #608 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 60.3%.
Is Bayer AG's EV-to-OCF too high?
Bayer AG's current EV-to-OCF of 14.76 is 69% above median its 10-year median of 8.72. Over the past 10 years, this metric has ranged from a low of 1.55 to a high of 22.70. The Drug Manufacturers industry median EV-to-OCF is 10.58. Bayer AG's value of 14.76 is 39.5% above this industry median. Based on the distribution chart, Bayer AG ranks #608 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bayer AG has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's EV-to-OCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #608 out of 1008 companies for EV-to-OCF. This places Bayer AG in the lower half of its industry. The industry median EV-to-OCF is 10.58. Bayer AG's value of 14.76 is 39.5% above this benchmark. Historically, Bayer AG's own EV-to-OCF has ranged from 1.55 to 22.70 over the past decade. While the company's 10-year median is 8.72 vs. the industry median of 10.58, Bayer AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.58, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bayer AG's current EV-to-OCF of 14.76 is 39.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current EV-to-OCF is 14.76, which is 69% above median its own 10-year median of 8.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.67, compared to a current price of CHF47.36 — trading 92% above its estimated fair value. The current EV-to-OCF is 14.76, which is 69% above median its 10-year median of 8.72 and 39.5% above the Drug Manufacturers industry median of 10.58. Bayer AG's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current EV-to-OCF is 14.76 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF47.36 is trading 92% above its estimated GF Value™ of CHF24.67.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
EV-to-OCF: 14.76 (69% above median its 10-year median of 8.72)
GF Value™: CHF24.67 vs. price of CHF47.36 (92% above fair value)
Industry Position: 39.5% above the Drug Manufacturers median (#608 of 1008)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
45GF Score
Get the complete analysis for XSWX:BAYN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 
